Pasar al contenido principal

MICROAMBIENTE INMUNE DEL TUMOR E IDENTIFICACION DE BIOMARCADORES DE RESPUESTA A LA QUIMIOTERAPIA O QUIMIOINMUNOTERAPIA NEOADYUVANTE EN PACIENTES CON CANCER DE PULMON DE CELULA NO PEQUEÑA

PI19/01652

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden, A Nonrandomized Controlled Trial

  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Ortega Granados, Ana Laura|||0000-0002-5727-3371
  • Coves-Sarto, Juan
  • Calvo, Virginia|||0000-0002-3503-4847
  • Marsé-Fabregat, Raquel
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Guirado Risueño, Maria|||0000-0001-9086-204X
  • Carcereny, Enric|||0000-0001-5235-5602
  • Fernández, Natalia
  • Álvarez, Ruth
  • Blanco, Remei|||0000-0001-6748-0326
  • León-Mateos, Luis
  • Sánchez Torres, José Miguel
  • Sullivan, Ivana|||0000-0002-0434-3436
  • Cobo, Manuel|||0000-0003-3402-1144
  • Sánchez Hernández, Alfredo|||0000-0001-5826-8390
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Mártinez-Toledo, Cristina
  • Serna-Blasco, Roberto
  • Romero, Atocha|||0000-0002-1634-7397
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
Antiangiogenic drug combinations with anti-programmed cell death 1 protein and anti-programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation burden (TMB) is unknown. To assess the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB advanced nonsquamous non-small cell lung cancer (NSCLC). This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. From May 2019 through January 2021, patients were assessed at 13 sites in Spain, with follow-up until February 28, 2022. Participants were given atezolizumab, 1200 mg, plus bevacizumab, 15 mg/kg, on day 1 of each 21-day cycle. Treatment was continued until documented disease progression, unacceptable toxic effects, patient withdrawal, investigator decision, or death. Main Outcomes and Measures: The primary end point was 12-month progression-free survival (PFS) rate (according to Response Evaluation Criteria in Solid Tumours, version 1.1 criteria); PFS was defined as the time from enrollment to disease progression or death. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A total of 307 patients were assessed for trial eligibility, of whom 266 were ineligible for enrollment. Of the 41 patients enrolled, 3 did not fulfill all inclusion criteria and were excluded. The remaining 38 patients (28 [73.7%] male; mean [SD] age, 63.7 [8.3] years) constituted the per-protocol population. The 12-month PFS rate was 51.3% (95% CI, 34.2%-66.0%), which met the primary end point. The 12-month overall survival (OS) rate was 72.0% (95% CI, 54.1%-83.9%). The median PFS was 13.0 months (95% CI, 7.9-18.0 months), and the median OS was not reached. Of the 38 patients, 16 (42.1%) achieved an objective response and 30 (78.9%) achieved disease control. The median time to response was 2.8 months (IQR, 2.8-3.58 months), with a median duration of response of 11.7 months (range, 3.57-22.4 months; the response was ongoing at cutoff). Of 16 responses, 8 (50.0%) were ongoing. Most adverse events were grade 1 or 2. For atezolizumab, the most common adverse events were fatigue (6 [15.8%]) and pruritus (6 [15.8%]). For bevacizumab, they were hypertension (10 [26.3%]) and proteinuria (4 [10.5%]). Drug discontinuation occurred in 2 patients receiving atezolizumab (5.3%) and 3 patients receiving bevacizumab (7.9%). PD-L1 levels were not associated with response, PFS, or OS. These findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC. ClinicalTrials.gov Identifier: NCT03836066.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Nadal, Ernest|||0000-0002-9674-5554
  • González Larriba, José Luis|||0000-0003-2631-0309
  • Insa, Amelia|||0000-0002-3438-6170
  • Sánchez Hernández, Alfredo|||0000-0001-5826-8390
  • Del Rosario García-Campelo, María|||0000-0003-2113-1504
  • Rogado, J.
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Ponce, S.
  • Reguart, Noemi|||0000-0001-8190-499X
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Aguilar, Alba
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Estival, Anna|||0000-0002-2788-9159
  • Cobo, Manuel|||0000-0003-3402-1144
  • Camps, Carlos|||0000-0002-0648-5403
  • Calvo, Virginia|||0000-0002-3503-4847
  • Collazo-Lorduy, Ana
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Romero, A.
  • Robado de Lope, Lucía
  • Serna-Blasco, Roberto
  • Diz Taín, Pilar|||0000-0003-4284-3965
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Casal-Rubio, Joaquín
  • Sequero López, S.
  • Vázquez Estévez, S.
  • Castro, Javier de|||0000-0002-3622-6306
  • Coves Sarto, J.
  • Peña Cabia, Silvia
  • López Martín, A.
  • Sala González, María Ángeles
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
Background: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods: Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results: The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78-2.85; P < 0.001). Conclusion: BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • García Campelo, María del Rosario
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Barquín, Miguel
  • Laza-Briviesca, Raquel
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Parra, Edwin R.|||0000-0001-9068-1636
  • Sanchez-Espiridion, Beatriz
  • Rocha, Pedro
  • Kadara, Humam
  • Wistuba, Ignacio I.
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). Experimental Design: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue samples of 40 patients with NSCLC, before and after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete pathologic response (CPR) or non-CPR. Beyond TCR metrics, tissue clones were ranked by their frequency and spatiotemporal evolution of top 1% clones was determined. Results: We have found a positive association between an uneven TCR repertoire in tissue samples at diagnosis and CPR at surgery. Moreover, TCR most frequently ranked clones (top 1%) present in diagnostic biopsies occupied greater frequency in the total clonal space of CPR patients, achieving an AUC ROC to identify CPR patients of 0.967 (95% confidence interval, 0.897-1.000; P ¼ 0.001), and improving the results of PD-L1 tumor proportion score (TPS; AUC = 0.767; P = 0.026) or tumor mutational burden (TMB; AUC = 0.550; P = 0.687). Furthermore, tumors with high pretreatment top 1% clonal space showed similar immune cell populations but a higher immune reactive gene expression profile. Finally, the selective expansion of pretreatment tissue top 1% clones in peripheral blood of CPR patients suggests also a peripheral immunosurveillance, which could explain the high survival rate of these patients. Conclusions: We have identified two parameters derived from TCR repertoire analysis that could outperform PD-L1 TPS and TMB as predictive biomarkers of CPR after neoadjuvant chemoimmunotherapy, and unraveled possible mechanisms of CPR involving enhanced tumor immunogenicity and peripheral immunosurveillance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Garitaonaindiá, Yago
  • Insa, Amelia|||0000-0002-3438-6170
  • Mosquera, Joaquín
  • Casal-Rubio, Joaquín
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López Vivanco, Guillermo
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Laza-Briviesca, Raquel
  • Casarrubios, Marta|||0000-0002-2872-9552
  • Garciá-Grande, Aránzazu
  • Romero, Atocha|||0000-0002-1634-7397
  • Franco, Fernando|||0000-0001-8964-5136
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. Methods In order to identify parameters associated to treatment related Pn, we analyzed clinical variables and molecular parameters from 46 patients with potentially resectable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapy included in the NADIM clinical trial (NCT03081689). Pn was defined as clinical or radiographic evidence of lung inflammation without alternative diagnoses, from treatment initiation to 180 days. Results Among 46 patients, 12 developed Pn (26.1%). Sex, age, smoking status, packs-year, histological subtype, clinical or pathological response, progression-free survival, overall survival and number of nivolumab cycles, were not associated to Pn development. Regarding molecular parameters at diagnosis, Pn development was not associated to programmed death ligand 1, TPS, T cell receptor repertoire parameters, or tumor mutational burden. However, patients who developed Pn had statistically significant lower blood median levels of platelet to monocyte ratio (p=0.012) and teratocarcinoma-derived growth factor 1 (p=0.013; area under the curve (AUC) 0.801), but higher median percentages of natural killers (NKs) (p=0.019; AUC 0.786), monocytes (p=0.017; AUC 0.791), MSP (p=0.006; AUC 0.838), PARN (p=0.017; AUC 0.790), and E-Cadherin (p=0.022; AUC 0.788). In addition, the immune scenario of Pn after neoadjuvant treatment involves: high levels of neutrophils and NK cells, but low levels of B and T cells in peripheral blood; increased clonality of intratumoral T cells; and elevated plasma levels of several growth factors (EGF, HGF, VEGF, ANG-1, PDGF, NGF, and NT4) and inflammatory cytokines (MIF, CCL16, neutrophil gelatinase-associated lipocalin, BMP-4, and u-PAR). Conclusions Although statistically underpowered, our results shed light on the possible mechanisms behind Pn development, involving innate and adaptative immunity, and open the possibility to predict patients at high risk. If confirmed, this may allow the personalization of both, the surveillance strategy and the therapeutic approaches to manage Pn in patients receiving chemoimmunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • Del Rosario García-Campelo, María|||0000-0003-2113-1504
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Martinez-Toledo, Cristina|||0000-0002-0663-0674
  • Fernández-Miranda, Ismael|||0000-0002-5136-7270
  • Serna-Blanco, Roberto|||0000-0002-7563-9613
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery. Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes. Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC).